Historical Valuation
Akari Therapeutics PLC (AKTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 106.79. The fair price of Akari Therapeutics PLC (AKTX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：0.29
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Akari Therapeutics PLC (AKTX) has a current Price-to-Book (P/B) ratio of 0.42. Compared to its 3-year average P/B ratio of -12.85 , the current P/B ratio is approximately -103.24% higher. Relative to its 5-year average P/B ratio of -1.25, the current P/B ratio is about -133.40% higher. Akari Therapeutics PLC (AKTX) has a Forward Free Cash Flow (FCF) yield of approximately -72.69%. Compared to its 3-year average FCF yield of -71.48%, the current FCF yield is approximately 1.70% lower. Relative to its 5-year average FCF yield of -54.62% , the current FCF yield is about 33.08% lower.
P/B
Median3y
-12.85
Median5y
-1.25
FCF Yield
Median3y
-71.48
Median5y
-54.62
Competitors Valuation Multiple
AI Analysis for AKTX
The average P/S ratio for AKTX competitors is 0.59, providing a benchmark for relative valuation. Akari Therapeutics PLC Corp (AKTX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for AKTX
1Y
3Y
5Y
Market capitalization of AKTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AKTX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is AKTX currently overvalued or undervalued?
Akari Therapeutics PLC (AKTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 106.79. The fair price of Akari Therapeutics PLC (AKTX) is between to according to relative valuation methord.
What is Akari Therapeutics PLC (AKTX) fair value?
AKTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Akari Therapeutics PLC (AKTX) is between to according to relative valuation methord.
How does AKTX's valuation metrics compare to the industry average?
The average P/S ratio for AKTX's competitors is 0.59, providing a benchmark for relative valuation. Akari Therapeutics PLC Corp (AKTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Akari Therapeutics PLC (AKTX) as of Jan 10 2026?
As of Jan 10 2026, Akari Therapeutics PLC (AKTX) has a P/B ratio of 0.42. This indicates that the market values AKTX at 0.42 times its book value.
What is the current FCF Yield for Akari Therapeutics PLC (AKTX) as of Jan 10 2026?
As of Jan 10 2026, Akari Therapeutics PLC (AKTX) has a FCF Yield of -72.69%. This means that for every dollar of Akari Therapeutics PLC’s market capitalization, the company generates -72.69 cents in free cash flow.
What is the current Forward P/E ratio for Akari Therapeutics PLC (AKTX) as of Jan 10 2026?
As of Jan 10 2026, Akari Therapeutics PLC (AKTX) has a Forward P/E ratio of -1.00. This means the market is willing to pay $-1.00 for every dollar of Akari Therapeutics PLC’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Akari Therapeutics PLC (AKTX) as of Jan 10 2026?
As of Jan 10 2026, Akari Therapeutics PLC (AKTX) has a Forward P/S ratio of 0.00. This means the market is valuing AKTX at $0.00 for every dollar of expected revenue over the next 12 months.